elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38297892-3C13DA72-7CD3-4AB4-B0DF-C2CD9A5CBE6E
Q38297892-3C13DA72-7CD3-4AB4-B0DF-C2CD9A5CBE6E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38297892-3C13DA72-7CD3-4AB4-B0DF-C2CD9A5CBE6E
Developing biomarker-specific end points in lung cancer clinical trials.
P2860
Q38297892-3C13DA72-7CD3-4AB4-B0DF-C2CD9A5CBE6E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38297892-3C13DA72-7CD3-4AB4-B0DF-C2CD9A5CBE6E
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f13f0359209a24333ca6cf423f79780b85c2b8b4
P2860
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.